Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/08/2007US20070053843 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
03/08/2007US20070053838 Comprises therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin (opioid growth factor); cancer
03/08/2007US20070053833 Hydrating a leukemia patient; parenterally administering a dose samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and melphalan, busulfan, and/or cyclophosphamiide; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
03/08/2007US20070053832 Drug product and process for making
03/08/2007DE112005000868T5 Nicht-GMO-Metallminosäure-Chelate und Zusammensetzungen, die Nicht-GMO-Metallaminosäure-Chelate enthalten Contain non-GMO Metallminosäure chelates and compositions non-GMO metal amino acid chelates
03/08/2007DE112004002170T5 Verbesserte Verfahren und Zusammensetzungen für RNA Interferenz Improved methods and compositions for RNA interference
03/08/2007DE10331253B4 Therapeutika gegen Parasiten von Fischen Therapeutics against parasites of fish
03/08/2007DE102005042742A1 Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel Substituted imidazo [1,2-b] pyridazines as kinase inhibitors, their production and use as a medicament
03/08/2007DE102005041760A1 New fredericamycin A derivatives with carbon-bonded B-ring substituent, are well tolerated topoisomerase I and/or II inhibitors especially useful for treating cancers or tumors
03/08/2007DE102005041613A1 Use of octahydro-indolo-quinoline compound in the preparation of pharmaceutical composition for the treatment and prophylaxis of gastrointestinal and endocardial disease and carcinoid syndrome
03/08/2007DE10161149B4 Verwendung von Heparin-haltigem Ophthalmikum Use of heparin-containing ophthalmic
03/08/2007CA2848021A1 Compostions and methods for preparation of poorly water soluble drugs with increased stability
03/08/2007CA2845095A1 methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/08/2007CA2822094A1 Isoindole-imide compounds and compositions comprising and methods of using the same
03/08/2007CA2670130A1 Heterobifunctional pan-selectin inhibitors
03/08/2007CA2627158A1 Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2receptor antagonist
03/08/2007CA2625940A1 Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents
03/08/2007CA2621377A1 Antitumor agent
03/08/2007CA2621229A1 Non-steroidal compounds useful as glucocorticoid receptor modulators
03/08/2007CA2621227A1 Thiazole derivative
03/08/2007CA2621201A1 Topical formulations
03/08/2007CA2621200A1 Transdermal active principle delivery means
03/08/2007CA2621182A1 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
03/08/2007CA2621162A1 Novel azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/08/2007CA2621157A1 Osteogenic and anti-adipogenic oxysterols
03/08/2007CA2621136A1 Immunological uses of immunodulatory compounds for vaccine and anti-infectious disease therapy
03/08/2007CA2621127A1 Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
03/08/2007CA2621117A1 Steroids nitrooxyderivatives
03/08/2007CA2621037A1 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
03/08/2007CA2621017A1 Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques
03/08/2007CA2620933A1 Hydroxy substituted 1h-imidazopyridines and methods
03/08/2007CA2620915A1 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
03/08/2007CA2620894A1 Novel benzopyran derivatives as potassium channel openers
03/08/2007CA2620864A1 Raf inhibitor compounds and methods of use thereof
03/08/2007CA2620856A1 Methods for use in modulating mir-122a
03/08/2007CA2620853A1 Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
03/08/2007CA2620846A1 Benzopyran and pyranopyridine derivatives as potassium channel openers
03/08/2007CA2620834A1 Use of fused imidazole derivatives to mediate ccr3 related conditions
03/08/2007CA2620818A1 Amide derivatives as rock inhibitors
03/08/2007CA2620777A1 Benzodiazepines as hcv inhibitors
03/08/2007CA2620742A1 Thiomorpholine compound and process for preparing the same
03/08/2007CA2620740A1 Pyridazinone derivatives used for the treatment of pain
03/08/2007CA2620688A1 Heterocyclic compound
03/08/2007CA2620685A1 Pharmaceutical composition comprising an iron chelator
03/08/2007CA2620683A1 Oxadiazole compounds as urokinase inhibitors
03/08/2007CA2620662A1 Pyrrolopyridine derivatives and use of same as ppar receptor modulators
03/08/2007CA2620658A1 Novel indole compounds
03/08/2007CA2620647A1 Combined preparation of a thiazide diuretic and a loop diuretic
03/08/2007CA2620631A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases
03/08/2007CA2620600A1 9-aminocarbonylsubstituted derivatives of glycylcyclines
03/08/2007CA2620585A1 Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
03/08/2007CA2620582A1 Methods of altering an immune response induced by cpg oligodeoxynucleotides
03/08/2007CA2620570A1 Niacin receptor agonists, compositions containing such compounds and methods of treatment
03/08/2007CA2620566A1 Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
03/08/2007CA2620553A1 Therapeutic agent for hypertension
03/08/2007CA2620534A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
03/08/2007CA2620512A1 Compositons comprising phosphatidic acid for treatment of eosinophilia and related disorders
03/08/2007CA2620469A1 Methods of modulating intestinal fluid balance
03/08/2007CA2620466A1 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as .beta.2 adrenoceptor agonists
03/08/2007CA2620429A1 Anti-inflammatory compositions and methods of use
03/08/2007CA2620425A1 Anilinopyrazole derivatives useful for the treatment of diabetes
03/08/2007CA2620406A1 Method for removing phosphate and polymer used therefore
03/08/2007CA2620400A1 Liposome compositions
03/08/2007CA2620389A1 Compositions and methods for preparation of poorly water soluble drugs with increased stability
03/08/2007CA2620352A1 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007CA2620269A1 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
03/08/2007CA2620255A1 Use of enoxaparin for performimg percutaneous coronary intervention
03/08/2007CA2620129A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007CA2620127A1 Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
03/08/2007CA2620085A1 Isoindole-imide compounds and compositions comprising and methods of using the same
03/08/2007CA2620034A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007CA2620023A1 Novel ansamycin derivatives
03/08/2007CA2620022A1 Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with staphylococcus aureus
03/08/2007CA2619919A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007CA2619912A1 Novel cycloalkane carboxamides as factor xa inhibitors
03/08/2007CA2619911A1 Pharmaceutical composition comprising perindopril or its salts
03/08/2007CA2619898A1 Diaminopyrimidines as p2x3 and p2x2/3 modulators
03/08/2007CA2619566A1 6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
03/08/2007CA2619565A1 Therapy for the treatment of disease
03/08/2007CA2619450A1 6-n-linked heterocycle-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
03/08/2007CA2619448A1 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
03/08/2007CA2619445A1 Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
03/08/2007CA2619438A1 Amorphous solid dispersions of 7-chloro-n,n, 5-trimethyl-4-oxo-3-phenyl-3, 5,-dihydro-4h-pyridazino(4,5-b) indole-1-acetamide
03/08/2007CA2619287A1 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
03/08/2007CA2619284A1 Novel crystalline form of a pyridazino [4,5-b] indole derivative
03/08/2007CA2619251A1 Use of dha in the form of phospholipids for the preparation of a composition that is intended for the treatment of respiratory failure
03/08/2007CA2617920A1 Argatroban formulation comprising an acid as solubilizer
03/08/2007CA2617495A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
03/08/2007CA2616797A1 Benzodiazepine derivatives , their preparation and the therapeutic use thereof
03/08/2007CA2616479A1 Treatment of optic neuritis
03/08/2007CA2616473A1 4-aryloxy quinoline derivatives as 5-ht6 modulators
03/08/2007CA2616468A1 Tricyclic 6-alkylidene-penem .beta.-lactamase inhibitors and .beta.-lactam antibiotic combination: a broad spectrum antibiotic
03/08/2007CA2615866A1 4-chromenonyl-1,4-dihydropyridines and their use
03/08/2007CA2614232A1 Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists
03/08/2007CA2614088A1 Use of soluble guanylate cyclase activators for treating reperfusion damage
03/08/2007CA2610668A1 Solid particulate tadalafil having a bimodal particle size distribution
03/08/2007CA2609026A1 Formulations containing losartan and/or its salts
03/08/2007CA2607999A1 Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid
03/08/2007CA2606851A1 Composition and method for treating nosebleeds
03/08/2007CA2606106A1 Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
1 ... 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 3866 3867 3868 ... 7860